close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

160.06 +1.86 (+1.18%)
Official Closing Price Updated: 7:00 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Drug Delivery Market – Major Technology Giants in Buzz Again : Johnson & Johnson, Sanofi, Pfizer
How to reach that market place and its associated audience with current marketing efforts? Benchmark now the competitive efforts with high growth emerging players and leaders of Drug Delivery Market. 
Via SBWire
News headline image
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Global Cell and Gene Therapy Market will worth USD 21,508 million by 2028-end at a CAGR of 28.2% from 2022 to 2028 according to Intelligence Market Report 
Via SBWire
News headline image
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
News headline image
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
From Erasca, Inc.
Via GlobeNewswire
VideoKrtoon Offers State Of The Art 2D Animation Services
Via Prodigy
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member
Via Investor Brand Network
News headline image
Why CSL Ltd Stock Could Be Worth a Look
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
Via MarketBeat
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break... 
Via TheNewswire.com
News headline image
Longwood Healthcare Leaders to Bring Together Several Hundred Top Biotech and Pharmaceutical Leaders on Jan. 5-6, 2023
Longwood Fund, an early-stage life science venture firm, will convene several hundred top biotech and pharmaceutical leaders at its Pre-JPM Longwood Healthcare Leaders meeting, hosted virtually via... 
Via Newswire.com
News headline image
Drug Repurposing Market to Eyewitness Huge Growth by 2027 : Allergan, Astellas Pharma, Biovista, NuMedii
Stay up-to-date with Drug Repurposing Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
News headline image
Leading Data Analytics Company Vizlib Gains ISO 27001 Certification
About Vizlib Vizlib has revolutionised the way businesses of every size can get more from their data analytics investment into Qlik. With over 1,000 enterprise and public sector clients across the... 
Via PRUnderground
Pharma Trend Honors the Best Pharmaceutical Companies and the Most Innovative Products 2022
Via Magic PR
News headline image
Global Topical Pain Relief Gel Industry Size,Chain Research Report 2022-2028:Johnson & Johnson, Novartis, GlaxoSmithKline
Global Topical Pain Relief Gel Industry Research Report, Growth Trends and Competitive Analysis 2022-2028 
Via SBWire
Topics Economy
News headline image
Bone Cancer Market Overview, Industry Top Manufactures, Size, Growth Rate 2022- 2028:Amgen, Baxter, Bayer
Bone Cancer Market - The new report on the global Bone Cancer Market comes out as an extremely useful resource that helpsplayers to gain a competitive edge over their toughest competitors. It can be... 
Via SBWire
Vasculitis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Novartis, Ambulero, InflaRx
Continue reading "Vasculitis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Novartis, Ambulero, InflaRx" 
Via Get News
News headline image
Smart Manufacturing Market Share 2022 Size, Key Trends, Future Scope, Global Outlook, Investment Plans and Development Status by 2027
Smart Manufacturing Market 2022 | Major Key Players included in this Report are Pfizer , Novartis, Abbott Laboratories and Many More with SWOT Analysis by 2027 
Via SBWire
News headline image
Appointment of Sachin Nanavati to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"... 
Via Newsfile
News headline image
SiO2 Materials Science Names Yves Steffen as Chief Executive Officer
SiO2 Materials Science today announced the Board of Directors has appointed Yves Steffen as CEO effective Aug. 1, 2022. 
Via Newswire.com
News headline image
NYSE:NVS Investor Alert: Investigation over Potential Wrongdoing at Novartis AG ↗
San Diego, CA -- (SBWIRE) -- 08/30/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Novartis AG. 
Via SBWire
News headline image
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of 
Via Spotlight Growth
News headline image
Emery Pharma Announces New Biologics Analytical Division
Supporting end-to-end research and development of large molecule drugs including, biologics, antibody-drug conjugates, biosimilars, and more 
Via Newswire.com
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
Via Investor Brand Network
Topics Intellectual Property
News headline image
Laboratory Testing Leader Pace® Science and Technology Company Names Nisheet Gupta as New Chief Financial Officer
Experienced financial leader Nisheet Gupta has been appointed Executive Vice President and Chief Financial Officer of Twin Cities-based Pace®, a leader and innovator in testing, analysis, and... 
Via Newswire.com
News headline image
Vizzia Technologies Named a Top 100 Healthcare Technology Company of 2022
Real-Time Data Analytics Service Provider Recognized for 2nd Consecutive Year 
Via Newswire.com
The Power of Science to Stop a Killer
Via Investor Brand Network
The Power of Science to Stop a Killer
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114... 
Via FinancialNewsMedia
News headline image
Amphetamine Drug Market 2022: Industry Analysis, Size, Global Trends, Share, Growth, Opportunity and Forecast to 2028
Amphetamine Drug Market SWOT Analysis Including Key Players Pfizer, Novartis, Eli Lilly, GSK, Hisamitsu Pharmaceutical, Purdue Pharma 
Via SBWire
News headline image
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Global Liposarcoma Treatment Market 2022 Business Strategies and Overview Report 2031 Taro Pharmaceuticals, Sandoz, Pfizer, Eli Lilly, Sanofi SA, Novartis AG
The intelligent report on the global Liposarcoma Treatment market provides deep analysis of the Liposarcoma Treatment industry segments including product type, application, special geographies and... 
Via SBWire
Topics Supply Chain
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today